Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Prazosin in Preventing Post-traumatic Stress Disorder

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patient of age \>18 years and \<65 years~* Victim of direct experience trauma (accident or physical aggression)~* Presence of an ASD between D3 and D7 after the trauma according to DSM V criteria~Exclusion Criteria:~* Contra-indication to prazosin: orthostatic hypotension, right heart failure, other hypotensive therapy, 5-phosphodiesterase inhibitors (sildenafil) or diuretic, history of syncope or severe unexplained faintness, hypersensitivity known to quinazolines.~* Alcohol and / or drug use at the time of the trauma~* History of psychotic disorder~* Suicidal risk defined by a score ≥ 2 on the Suicidal Ideas Item of the Beck Depression Inventory (BDI)~* Protected or vulnerable Major~* Persistence of a life threatening injury at D3~* Sexual assault~* Only moderate head trauma can be included and therefore excluded patients with loss of consciousness greater than 30 minutes, Glasgow score less than 13, post-traumatic amnesia greater than 24 hours (Ruff et al., 2009) .~* Prescription of morphine or morphine derivative in progress~* Pregnancy or breastfeeding period~* Lack of effective contraception in a woman susceptible to childbearing~* Known hepatic dysfunction~* Narcolepsy (Gelineau's disease)~* Cardiac or vascular history including coronary artery disease~* Strict low-sodium diet

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Prazosin, ALPRESS® LP 2,5 et 5 mg (Type: EXPERIMENTAL): Patients included in this study will be adults with acute stress as a result of a direct experience traumatic event. They will be treated with Prazosin, ALPRESS® LP 2,5 et 5 mg during 28 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).